Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation

María José Serna; José Miguel Rivera‐Caravaca; Rocío Gónzález‐Conejero; María Asunción Esteve‐Pastor; Mariano Valdés; Vicente Vicente; Professor Gregory Lip; Vanessa Roldán; Francisco Marı́n

doi:10.1111/eci.12929

Abstract

1 min read

Adding pharmacogenetic factors (ie polymorphisms of the VKORC1 and CYP2C9 genes) to the HAS-BLED score does not improve the prediction or discrimination performance for major bleeding.

Related publications

Article2017

Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation

José Miguel Rivera‐Caravaca, Vanessa Roldán, María Asunción Esteve‐Pastor, Mariano Valdés, Vicente Vicente, Professor Gregory Lip, Francisco Marı́n

Article2019

Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores

José Miguel Rivera‐Caravaca, Francisco Marı́n, Juan A. Vílchez, Josefa Gálvez, María Asunción Esteve‐Pastor, Vicente Vicente, Professor Gregory Lip, Vanessa Roldán

Article2018

Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS‐BLED and GARFIELD‐AF Bleeding Scores

Marco Proietti, José Miguel Rivera‐Caravaca, María Asunción Esteve‐Pastor, Giulio Francesco Romiti, Francisco Marı́n, Professor Gregory Lip

Article2017

Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial

María Asunción Esteve‐Pastor, José Miguel Rivera‐Caravaca, Alena Shantsila, Vanessa Roldán, Professor Gregory Lip, Francisco Marı́n

Article2016

Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores

Marco Proietti, Keitaro Senoo, Deirdre A. Lane, Professor Gregory Lip